Maxim Group Rates VolitionRx (VNRX) buy, $4 Price Target
Maxim Group reinstated its 'buy' rating on VNRX with a $4 price target, a 179.72% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Maxim Group rated VolitionRx Limited ($VNRX) "buy" with a $4 price target on June 18, 2026.
Since the rating, $VNRX is down 9.8% after 1 week, down 21.0% after 1 month and down 87.4% to date (from the $1.43 close on Jun 18, 2026).
VNRX
VolitionRx Limited
Key Points
- Maxim Group reinstated its 'buy' rating on VNRX with a $4 price target on June 18, 2026.
- Maxim Group's $4 price target implies 179.72% upside from VolitionRx Limited's ($VNRX) current $1.43 share price.
- VNRX shares traded around $1.43, with recent insider sales by company executives.
- Institutional investors like Lagoda Investment Management reduced their holdings significantly.
Get $VNRX trade alerts by text
We text you when insiders, Congress or big funds trade $VNRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated VolitionRx Limited alert may contain errors. Disclosures
Maxim Group has reinstated its coverage of VNRX with a 'buy' rating and set a price target of $4, according to analyst Michael Okunewitch. This announcement was made on June 18, 2026, and comes as the stock trades around $1.43.
Other Institutional Activity in VNRX
Several institutional investors have recently adjusted their positions in VNRX. Lagoda Investment Management, L.P. significantly reduced its stake by 10,656,153 shares, ending with 807,450 shares valued at about $3.26 million. Meanwhile, Silverberg Bernstein Capital Management LLC slightly increased its holdings by 1,933 shares to 251,215 shares, worth approximately $50,745. Geode Capital Management, LLC also cut its position by 902,482 shares, leaving it with 61,504 shares valued at $248,510. Vanguard Capital Management LLC and Luminus Management LLC both established new positions, each holding 50,684 and 49,750 shares respectively.
VolitionRx Limited Stock Up 450.0%
VNRX shares are currently trading near $1.43. The stock has seen significant volatility as institutional investors adjust their positions and analysts update their ratings.
$VNRX price target
VolitionRx Limited daily closes and this analyst's $4 target. Not advice.
Insider Buying and Selling at VolitionRx Limited
Recent insider activity at VNRX includes several sales by company executives. On March 17, 2026, Nicholas Plummer, General Counsel at Volition Diagnostics, sold 7,003 shares at an average price of $0.19. Similarly, Chief Scientific Officer Jacob Vincent Micallef sold 5,310 shares at the same price. Secretary Rodney Gerard Rootsaert and Chief Commercial Officer Gael Forterre also sold shares on the same day.
Analysts Set New Price Targets
On June 18, 2026, Maxim Group reinstated its coverage of VNRX with a 'buy' rating and a $4 price target. This follows other recent analyst activity, such as HC Wainwright & Co. maintaining a 'buy' rating with a $1 target on April 2, 2026, and D. Boral Capital maintaining a 'buy' with a $3 target on March 31, 2026. The consensus among analysts remains positive with a 'buy' recommendation.
Bottom Line
The recent analyst activity and institutional changes reflect ongoing interest and adjustments in VNRX's stock, with Maxim Group's reinstated 'buy' rating and $4 target suggesting potential upside. Investors often track these updates for insights, though it's important to remember that 13F filings and analyst ratings are backward-looking and may not reflect current conditions.
Related Filing Alerts
Source: Maxim Group's rating change on $VNRX (Jun 18, 2026). Written by software, not financial advice. How we make alerts